A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects With Metastatic or Locally-advanced Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs STI-A1015 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Aug 2018 Status changed from planning to recruiting.
- 09 Feb 2018 New trial record